InThought: There is a high unmet need for therapeutic options for SjD and ianalumab will have a first mover advantage ahead of several competitors, as well as a dosing benefit that could be monthly or even quarterly
281 By reducing macrophage-mediated inflammatory responses, GLP-1RAs have the potential to alleviate symptoms of OA, including pain and joint stiffness
In clinical trials, the most common observations were gastrointestinal effects: nausea (44.2% vs 17.4% placebo in STEP 1), diarrhea (30.0%), vomiting (24.8%), and constipation (24.2%)
Experiments were performed to characterize the pharmacokinetics, absorption, distribution, metabolism, and excretion characteristics of BPC157 in rats and dogs
Interestingly, after cecum perforation, with BPC 157 administration we documented the gross reappearance of the vessels (USB micro camera) quickly propagating toward the defect at the caecum surface, defect in contraction, bleeding attenuation, MDA- and NO-levels normalized in colon tissue at 15 minutes, and advanced healing of colon lesions and less adhesions at days 1 and 7
In the myocardium affected by various pathological factors, the inhibition of GSH and GPX4 is ubiquitous